Smoking and opioid detoxification: Behavioral changes and response to treatment

Nicotine and Tobacco Research

Volumn 15, Issue 10, 2013, Pages 1705-1713

  Mannelli, Paolo ^a   Wu, Li Tzy ^a   Peindl, Kathleen S ^a   Gorelick, David A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NALTREXONE; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 84894284119     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntt046     Document Type: Article

References (69)

1. Back, S. E., Payne, R. L., Wahlquist, A. H., Carter, R. E., Stroud, Z., Haynes, L., et al. (2011). Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial. American Journal of Drug and Alcohol Abuse, 37, 313-323. doi:10.3109/00952990.2011.596982
2. Berrendero, F., Robledo, P., Trigo, J. M., Martin-Garcia, E., & Maldonado, R. (2010). Neurobiological mechanisms involved in nicotine dependence and reward: Participation of the endogenous opioid system. Neuroscience and Biobehavioral Review, 35, 220-231. doi:10.1016/j.neubiorev.2010.02.006
3. Bigelow, G. E., Stitzer, M. I., Griffiths, R. R., & Liebson, I. A. (1981). Human methadone detoxification: Opioid selfadministration behavior, cigarette smoking, and withdrawal signs and symptoms as a function of progressive dose reductions. Federation Proceedings, 40(3), 296.
4. Blazer, D. G., & Wu, L. T. (2012). Patterns of tobacco use and tobacco-related psychiatric morbidity and substance use among middle-aged and older adults in the United States. Aging and Mental Health, 16, 296-304. doi:10.1080/13607 863.2011.615739
5. Bruijnzeel, A. W., Bauzo, R. M., Munikoti, V., Rodrick, G. B., Yamada, H., Fornal, C. A., et al. (2011). Tobacco smoke diminishes neurogenesis and promotes gliogenesis in the dentate gyrus of adolescent rats. Brain Research, 1413, 32- 42. doi:10.1016/j.brainres.2011.07.041
6. Campbell, B. K., Wander, N., Stark, M. J., & Holbert, T. (1995). Treating cigarette smoking in drug-abusing clients. Journal of Substance Abuse Treatment, 12, 89-94.
7. Centers for Disease Control and Prevention. (2011). Vital signs: Current cigarette smoking among adults aged ≥18 years- United States, 2005-2010. Morbidity and Mortality Weekly Report, 60, 1207-1212.
8. Clark, R. E., Samnaliev, M., Baxter, J. D., & Leung, G. Y. (2011). The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs (Millwood), 30, 1425-1433. doi:10.1377/hlthaff.2010.0532
9. Clarke, J. G., Stein, M. D., McGarry, K. A., & Gogineni, A. (2001). Interest in smoking cessation among injection drug users. American Journal of Addictions, 10, 159-166.
10. Clemmey, P., Brooner, R., Chutuape, M. A., Kidorf, M., & Stitzer, M. (1997). Smoking habits and attitudes in a methadone maintenance treatment population. Drug and Alcohol Dependence, 44, 123-132.
11. Conner, B. T., Stein, J. A., Longshore, D., & Stacy, A. W. (1999). Associations between drug abuse treatment and cigarette use: Evidence of substance replacement. Experimental and Clinical Psychopharmacology, 7, 64-71.
12. Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010). Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. British Medical Journal, 341, c5475. doi:10.1136/bmj.c5475
13. Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001). Evaluation of the brief questionnaire of smoking urges (QSU-Brief) in laboratory and clinical settings. Nicotine & Tobacco Research, 3, 7-16. doi:10.1080/14622200020032051
14. David, S., Lancaster, T., Stead, L. F., & Evins, A. E. (2006). Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews, (4), CD003086. doi:10.1002/14651858. CD003086.pub2
15. Dols, M., van den Hout, M., Kindt, M., & Willems, B. (2002). The urge to smoke depends on the expectation of smoking. Addiction, 97, 87-93.
16. Domino, E. F., Evans, C. L., Ni, L., Guthrie, S. K., Koeppe, R. A., & Zubieta, J. K. (2012). Tobacco smoking produces greater striatal dopamine release in G-allele carriers with mu opioid receptor A118G polymorphism. Progress in Neuropsychopharmacology and Biological Psychiatry, 38, 236-240. doi:10.1016/j.pnpbp.2012.04.003
17. Elkader, A. K., Brands, B., Selby, P., & Sproule, B. A. (2009). Methadone-nicotine interactions in methadone maintenance treatment patients. Journal of Clinical Psychopharmacology, 29, 231-238. doi:10.1097/JCP.0b013e3181a39113
18. Engströ, A., Adamsson, C., Allebeck, P., & Rydberg, U. (1991). Mortality in patients with substance abuse: A followup in Stockholm County, 1973-1984. International Journal of the Addictions, 26, 91-106.
19. Epstein, A. M., & King, A. C. (2004). Naltrexone attenuates acute cigarette smoking behavior. Pharmacology, Biochemistry, and Behavior, 77, 29-37.
20. Faber, M. S., & Fuhr, U. (2004). Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clinical and Pharmacological Therapeutics, 76, 178-184. doi:10.1016/j.clpt.2004.04.003
21. First, M., Spitzer, R., Gibbon, M., & Williams, J. (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders (Research Version, Patient Edition (SCID-I/P)). New York, NY: Biometrics Research.
22. Frosch, D. L., Nahom, D., & Shoptaw, S. (2002). Optimizing smoking cessation outcomes among the methadone maintained. Journal of Substance Abuse Treatment, 23, 425-430.
23. Frosch, D. L., Shoptaw, S., Jarvik, M. E., Rawson, R. A., & Ling, W. (1998). Interest in smoking cessation among methadone maintained outpatients. Journal of Addictive Disorders, 17, 9-19. doi:10.1300/J069v17n02_02
24. Frosch, D. L., Shoptaw, S., Nahom, D., & Jarvik, M. E. (2000). Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. Experimental and Clinical Psychopharmacology, 8, 97-103.
25. Gorelick, D. A., Rose, J., & Jarvik, M. E. (1988). Effect of naloxone on cigarette smoking. Journal of Substance Abuse, 1, 153-159.
26. Gourlay, S., Stead, L., & Benowitz, N. (2004). Clonidine for smoking cessation. Cochrane Database of Systematic Reviews, (3), CD000058.
27. Guydish, J., Passalacqua, E., Tajima, B., Chan, M., Chun, J., & Bostrom, A. (2011). Smoking prevalence in addiction treatment: A review. Nicotine & Tobacco Research, 13, 401-411. doi:10.1093/ntr/ntr048
28. Haas, A. L., Sorensen, J. L., Hall, S. M., Lin, C., Delucchi, K., Sporer, K., et al. (2008). Cigarette smoking in opioidusing patients presenting for hospital-based medical services. American Journal of Addictions, 17, 65-69. doi:10.1080/10550490701756112
29. Handelsman, L., Cochrane, K. J., Aronson, M. J., Ness, R., Rubinstein, K. J., & Kanof, P. D. (1987). Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse, 13, 293-308. doi:10.3109/00952998709001515
30. Harrell, P. T., Montoya, I. D., Preston, K. L., Juliano, L. M., & Gorelick, D. A. (2011). Cigarette smoking and short-term addiction treatment outcome. Drug and Alcohol Dependence, 115, 161-166. doi:10.1016/j.drugalcdep.2010.08.017
31. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerstr? Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
32. Herman, A. I., & Sofuoglu, M. (2010). Comparison of available treatments for tobacco addiction. Current Psychiatry Reports, 12, 433-440. doi:10.1007/s11920-010-0134-6
33. Hooten, W. M., Townsend, C. O., Bruce, B. K., & Warner, D. O. (2009). The effects of smoking status on opioid tapering among patients with chronic pain. Anesthesia and Analgesia, 108, 308-315. doi:10.1213/ane.0b013e31818c7b99
34. Hser, Y. I., McCarthy, W. J., & Anglin, M. D. (1994). Tobacco use as a distal predictor of mortality among long-term narcotics addicts. Prevention Medicine, 23, 61-69. doi:10.1006/ pmed.1994.1009
35. Hughes, J. R. (1992). Tobacco withdrawal in self-quitters. Journal of Consulting and Clinical Psychology, 60, 689-697.
36. Hughes, J. R., Gulliver, S. B., Fenwick, J. W., Valliere, W. A., Cruser, K., Pepper, S., et al. (1992). Smoking cessation among self-quitters. Health Psychology, 11, 331-334.
37. Kalman, D., Morissette, S. B., & George, T. P. (2005). Co-morbidity of smoking in patients with psychiatric and substance use disorders. American Journal of Addictions, 14, 106-123. doi:10.1080/10550490590924728
38. Kanof, P. D., Handelsman, L., Aronson, M. J., Ness, R., Cochrane, K. J., & Rubinstein, K. J. (1992). Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. Journal of Pharmacology and Experimental Therapeutics, 260, 355-363.
39. Kapur, B. M., Hutson, J. R., Chibber, T., Luk, A., & Selby, P. (2011). Methadone: A review of drug-drug and pathophysiological interactions. Critical Review of Clinical and Laboratory Science, 48, 171-195. doi:10.3109/10408363.2011.620601
40. Knott, V. J., Raegele, M., Fisher, D., Robertson, N., Millar, A., McIntosh, J., et al. (2005). Clonidine pre-treatment fails to block acute smoking-induced EEG arousal/mood in cigarette smokers. Pharmacology Biochemistry and Behavior, 80, 161-171. doi:10.1016/j.pbb.2004.10.025
41. Liu, X., & Jernigan, C. (2011). Activation of the opioid mu1, but not delta or kappa, receptors is required for nicotine reinforcement in a rat model of drug selfadministration. Progress in Neuropsychopharmacology and Biological Psychiatry, 35, 146-153. doi:10.1016/ j.pnpbp.2010.10.007
42. Mannelli, P., Gottheil, E., Peoples, J. F., Oropeza, V. C., & Van Bockstaele, E. J. (2004). Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. Biological Psychiatry, 56, 261-268. doi:10.1016/j. biopsych.2004.05.013
43. Mannelli, P., Patkar, A. A., Peindl, K., Gorelick, D. A., Wu, L. T., & Gottheil, E. (2009). Very low dose naltrexone addition in opioid detoxification: A randomized, controlled trial. Addiction Biology, 14, 204-213. doi: 10.1111/j.1369-1600.2008.00119.x
44. Martinotti, G., Cloninger, C., & Janiri, L. (2008). Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. American Journal of Drug and Alcohol Abuse, 34, 177-183. doi:10.1080/ 00952990701877078
45. McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G. et al. (1992). The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment, 9, 199-213.
46. Mello, N. K., Lukas, S. E., & Mendelson, J. H. (1985). Buprenorphine effects on cigarette smoking. Psychopharmacology (Berlin), 86, 417-425.
47. Mello, N. K., Mendelson, J. H., Sellers, M. L., & Kuehnle, J. C. (1980). Effects of heroin self-administration on cigarette smoking. Psychopharmacology (Berlin), 67, 45-52.
48. Mutschler, N. H., Stephen, B. J., Teoh, S. K., Mendelson, J. H., & Mello, N. K. (2002). An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine & Tobacco Research, 4, 223-228. doi:10.1080/14622200 210124012
49. Okoli, C. T., Khara, M., Procyshyn, R. M., Johnson, J. L., Barr, A. M., & Greaves, L. (2010). Smoking cessation interventions among individuals in methadone maintenance: A brief review. Journal of Substance Abuse Treatment, 38, 191-199. doi:10.1016/j.jsat.2009.10.001
50. Ong, M. K., Zhou, Q., & Sung, H. Y. (2011). Primary care providers advising smokers to quit: Comparing effectiveness between those with and without alcohol, drug, or mental disorders. Nicotine & Tobacco Research, 13, 1193-1201. doi:10.1093/ntr/ntr167
51. Piper, M. E., Schlam, T. R., Cook, J. W., Sheffer, M. A., Smith, S. S., Loh, W. Y., et al. (2011). Tobacco withdrawal components and their relations with cessation success. Psychopharmacology (Berlin), 216, 569-578. doi:10.1007/ s00213-011-2250-3
52. Prochaska, J. J. (2010). Failure to treat tobacco use in mental health and addiction treatment settings: A form of harm reduction? Drug and Alcohol Dependence, 110, 177-182. doi:10.1016/j.drugalcdep.2010.03.002
53. Reid, M. S., Jiang, H., Fallon, B., Sonne, S., Rinaldi, P., Turrigiano, E., et al. (2011). Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: Exploring predictors of outcome as clues toward treatment improvement. American Journal of Drug and Alcohol Abuse, 37, 472-478. doi:10.3109/00952 990.2011.596981
54. Richter, K. P., Choi, W. S., McCool, R. M., Harris, K. J., & Ahluwalia, J. S. (2004). Smoking cessation services in U.S. methadone maintenance facilities. Psychiatric Services, 55, 1258-1264. doi:10.1176/appi.ps.55.11.1258
55. Richter, K. P., Gibson, C. A., Ahluwalia, J. S., & Schmelzle, K. H. (2001). Tobacco use and quit attempts among methadone maintenance clients. American Journal of Public Health, 91, 296-299.
56. Richter, K. P., Hamilton, A. K., Hall, S., Catley, D., Cox, L. S., & Grobe, J. (2007). Patterns of smoking and methadone dose in drug treatment patients. Experimental Clinical Psychopharmacology, 15, 144-153. doi:10.1037/ 1064-1297.15.2.144
57. Sheskin, D. (2004). Handbook of parametric and nonparametric statistical procedures (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC.
58. Shoptaw, S., Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, D., Jarvik, M. E., et al. (2002). Smoking cessation in methadone maintenance. Addiction, 97, 1317-1328.
59. Sobell, L. C., Brown, J., Leo, G. I., & Sobell, M. B. (1996). The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug and Alcohol Dependence, 42, 49-54.
60. Spiga, R., Martinetti, M. P., Meisch, R. A., Cowan, K., & Hursh, S. (2005). Methadone and nicotine self-administration in humans: A behavioral economic analysis. Psychopharmacology (Berlin), 178, 223-231. doi:10.1007/ s00213-004-2020-6
61. Spiga, R., Schmitz, J., & Day, J., II. (1998). Effects of nicotine on methadone self-administration in humans. Drug and Alcohol Dependence, 50, 157-165.
62. Stapleton, J. A., Keaney, F., & Sutherland, G. (2009). Illicit drug use as a predictor of smoking cessation treatment outcome. Nicotine & Tobacco Research, 11, 685-689. doi:10.1093/ ntr/ntp050
63. Substance Abuse and Mental Health Services Administration. (2010). Heroin and other opiate admissions to substance abuse treatment. The TEDS report. Rockville, MD: Author.
64. van den Brink, W. (2012). Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Current Drug Abuse Reviews, 5, 3-31.
65. Vlachou, S., Paterson, N. E., Guery, S., Kaupmann, K., Froestl, W., Banerjee, D., et al. (2011). Both GABAB receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats. European Journal of Pharmacology, 655, 52-58. doi:10.1016/j.ejphar.2011.01.009
66. Wahawisan, J., Kolluru, S., Nguyen, T., Molina, C., & Speake, J. (2011). Methadone toxicity due to smoking cessation: A case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. Annals of Pharmacotherapy, 45, e34. doi:10.1345/aph.1P759
67. Weinberger, A. H., Reutenauer, E. L., Vessicchio, J. C., & George, T. P. (2008). Survey of clinician attitudes toward smoking cessation for psychiatric and substance abusing clients. Journal of Addictive Disorders, 27, 55-63. doi:10.1300/ J069v27n01_06
68. Wise, R. A. (2008). Dopamine and reward: The anhedonia hypothesis 30 years on. Neurotoxicology Research, 14, 169- 183. doi:10.1007/BF03033808
69. Ziedonis, D. M., Amass, L., Steinberg, M., Woody, G., Krejci, J., Annon, J. J., et al. (2009). Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug and Alcohol Dependence, 99, 28-36. doi:10.1016/j. drugalcdep.2008.06.016